Literature DB >> 8664929

The effect of an accelerated immunisation schedule on pertussis in England and Wales.

J M White1, C K Fairley, D Owen, R C Matthews, E Miller.   

Abstract

Notifications of pertussis in England and Wales have fallen dramatically from 65 810 during the epidemic year of 1982 to 3963 cases during the epidemic year of 1994, as vaccine coverage has risen. The incidence of pertussis has declined in all ages, including babies under 3 months of age who would have been at risk of disease from older siblings vaccinated under the accelerated schedule introduced in 1990 if immunity induced as result of this schedule had been short lived. To document the efficacy of the current whole cell vaccine under the accelerated schedule an enhanced surveillance scheme based on laboratory confirmed cases of pertussis was set up in 1994. Three deaths occurred in infants with confirmed pertussis, all of whom were under 8 weeks of age and unvaccinated. The overall vaccine efficacy for those over 6 months and under 5 years of age was 94%. This estimate may be inflated, as a number of biases could lead to the underascertainment of cases in vaccinated children, but it is similar to previous estimates obtained for children of the same age vaccinated under the 3, 5, and 10 month schedule. Vaccine efficacy was 89% for children aged over 5 and under 15 years. The enhanced surveillance scheme will enable us to monitor the duration of protection under the accelerated schedule and evaluate the continuing impact of pertussis infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8664929

Source DB:  PubMed          Journal:  Commun Dis Rep CDR Rev        ISSN: 1350-9349


  5 in total

Review 1.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

Review 2.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Pertussis complications in Germany--3 years of hospital-based surveillance during the introduction of acellular vaccines.

Authors:  P Herzig; C Hartmann; D Fischer; J Weil; R von Kries; G Giani; H Schroten; C H Wirsing von König
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

4.  The distribution over time of costs and social net benefits for pertussis immunization programs.

Authors:  Dorota Zdanowska Girard
Journal:  Int J Health Care Finance Econ       Date:  2009-03-18

Review 5.  Perplexities of pertussis: recent global epidemiological trends and their potential causes.

Authors:  D W Jackson; Pejman Rohani
Journal:  Epidemiol Infect       Date:  2013-01-16       Impact factor: 4.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.